Healthcare costs were estimated for 12,998 PCI patient-procedures from the Melbourne Interventional Group (MIG) registry, collected between February 2004 and October 2010. Information collected included the use of cardiovascular drugs and cardiac-related hospitalisations from those that completed 12-month follow-up. Individual patients were assigned unit costs based on published data from the National Hospital Cost Data Collection for Admissions in Victoria (2008-2009) and the Pharmaceutical Benefit Scheme (PBS) schedule (2011-2012). Bootstrap multiple linear regression was used to estimate the direct excess healthcare costs, adjusting for age and gender and relevant comorbidities.
Excess cardiac-related readmissions occurred among patients with ¡°severe CKD or dialysis¡± (estimated glomerular filtration rate (eGFR): < 30 ml/min/1.73 m2; n = 330; 35 % ), compared to ¡°moderate CKD¡± (eGFR: 30-60 ml/min/1.73 m2; n = 2648; 28 % ), or the ¡°referent CKD status¡± (eGFR: ¡Ý 60 ml/min/1.73 m2; n = 10,020; 24 % ). On average, excess (95 % CI) overall direct costs were significantly higher in patients with severe CKD or dialysis compared to those with referent CKD status [$AUD 2206 ($AUD 1148 to 3688)].
From the healthcare payer's perspective, PCI patients with severe CKD compared to no-CKD imposed significantly higher burden on subsequent healthcare resources. Hospitalisations accounted for the majority of these expenditures.